Azitra Inc (AZTR)

$0.17 -0.01 (-6.67%)
Market Cap 3.72M
Revenue (ttm) 10,000.00
Net Income (ttm) -8.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,700.00%
Debt to Equity Ratio 0.00
Volume 1,102,900
Avg Vol 2,473,168
Day's Range N/A - N/A
Shares Out 20.68M
Stochastic %K 12%
Beta -1.62
Analysts Strong Sell
Price Target $2.50

Company Profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular ras...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 646 6446
Address:
21 Business Park Drive, Branford, United States
dln101
dln101 Aug. 7 at 3:21 PM
$AZTR this penny looks done dumping, bounce from here with other pennies $KAVL $BTOG 🤔💪📈
1 · Reply
Sky360
Sky360 Aug. 5 at 6:51 PM
$AZTR Key Factors Influencing Azitra’s Next Financial Report Historical Financial Performance1 Q1 2025 Results: EPS: Improved year-over-year (YoY) to -$0.23, up 94.68% from prior periods, but still deeply negative. Cash Burn: Operating cash flow was -$3.07M, while financing activities provided $1.75M via capital raises. Revenue: Minimal at $7.5K in Q2 2024 (latest reported revenue), highlighting reliance on funding over commercial traction. Upcoming Estimates 626 Consensus EPS for Q2 2025: Expected to narrow slightly to -$0.21, reflecting ongoing losses typical of clinical-stage biopharma firms. EBIT Forecast: Projected to worsen to -$3.4M (vs. -$3.07M in Q1 2025), likely due to increased R&D spending for clinical trials. Revenue Expectations: Analysts anticipate $0.000 for Q2 2025, consistent with the company’s pre-revenue status.
1 · Reply
triclkbao1
triclkbao1 Aug. 5 at 1:28 PM
$AZTR Er on 8/12.
0 · Reply
pbacher
pbacher Aug. 4 at 5:00 PM
$AZTR ...
0 · Reply
pbacher
pbacher Aug. 1 at 2:54 PM
$AZTR is this manipulation or just bullshit? didn´t get it...
0 · Reply
Stmkr
Stmkr Aug. 1 at 2:43 PM
$AZTR Wow. Not good...
2 · Reply
EdgeLeak
EdgeLeak Jul. 31 at 7:37 PM
$AZTR For accountability I have sold aLL - 38k loss - was a hero or zero type of setup - GLTA
0 · Reply
pbacher
pbacher Jul. 31 at 7:33 PM
$AZTR unbelievable...
0 · Reply
pbacher
pbacher Jul. 31 at 3:47 PM
$AZTR what a shit show. Dont know why I'm atill here =D maybe for the sentiment
0 · Reply
pbacher
pbacher Jul. 31 at 3:16 PM
$AZTR great work so far =D which bottom do you mean?
0 · Reply
Latest News on AZTR
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Jun 17, 2025, 8:02 AM EDT - 7 weeks ago

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Jun 10, 2025, 8:33 AM EDT - 2 months ago

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

May 28, 2025, 8:33 AM EDT - 2 months ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

May 14, 2025, 4:05 PM EDT - 3 months ago

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

May 13, 2025, 5:06 PM EDT - 3 months ago

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 25, 2025, 8:33 AM EDT - 3 months ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Apr 24, 2025, 4:05 PM EDT - 3 months ago

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Azitra to Present at Microbiome Times Partnering Forum

Mar 12, 2025, 8:33 AM EDT - 5 months ago

Azitra to Present at Microbiome Times Partnering Forum

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:30 AM EST - 5 months ago

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Feb 4, 2025, 2:20 PM EST - 6 months ago

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Feb 3, 2025, 9:05 AM EST - 6 months ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Azitra, Inc. to Present at The Microcap Conference

Jan 27, 2025, 4:05 PM EST - 6 months ago

Azitra, Inc. to Present at The Microcap Conference

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Jan 15, 2025, 8:30 AM EST - 7 months ago

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Azitra Announces Proposed Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 7 months ago

Azitra Announces Proposed Public Offering of Common Stock

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Nov 12, 2024, 5:05 PM EST - 9 months ago

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Azitra to Present at BIO-Europe 2024

Oct 29, 2024, 9:00 AM EDT - 10 months ago

Azitra to Present at BIO-Europe 2024

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 11, 2024, 9:00 AM EDT - 10 months ago

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Sep 24, 2024, 8:00 AM EDT - 11 months ago

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Sep 18, 2024, 9:00 AM EDT - 11 months ago

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 4:30 PM EDT - 11 months ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 20, 2024, 4:15 PM EDT - 1 year ago

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 6:23 PM EDT - 1 year ago

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Jul 25, 2024, 5:57 PM EDT - 1 year ago

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

Jul 25, 2024, 1:54 PM EDT - 1 year ago

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

HAL

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

Jul 25, 2024, 1:13 PM EDT - 1 year ago

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

HAL

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Jul 23, 2024, 9:20 PM EDT - 1 year ago

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Azitra, Inc. Announces Reverse Stock Split

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Azitra, Inc. Announces Reverse Stock Split

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

May 31, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

May 17, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

May 10, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

May 9, 2024, 5:00 PM EDT - 1 year ago

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 15, 2024, 4:15 PM EDT - 1 year ago

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Azitra, Inc. Announces Closing of Public Offering

Feb 16, 2024, 4:05 PM EST - 1 year ago

Azitra, Inc. Announces Closing of Public Offering

Azitra, Inc. Announces Pricing of Public Offering

Feb 13, 2024, 10:09 PM EST - 1 year ago

Azitra, Inc. Announces Pricing of Public Offering

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Jan 16, 2024, 9:00 AM EST - 1 year ago

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

Jan 3, 2024, 9:00 AM EST - 1 year ago

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

Nov 14, 2023, 4:30 PM EST - 1 year ago

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

Azitra to Present at the ThinkEquity Conference

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Azitra to Present at the ThinkEquity Conference

Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates

Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors

Jul 19, 2023, 4:05 PM EDT - 2 years ago

Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

Azitra, Inc. Announces Closing of Initial Public Offering

Jun 21, 2023, 6:46 PM EDT - 2 years ago

Azitra, Inc. Announces Closing of Initial Public Offering

Azitra, Inc. Announces Pricing of Initial Public Offering

Jun 15, 2023, 7:04 PM EDT - 2 years ago

Azitra, Inc. Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: No IPOs, But The Pipeline Gets A Pickup With 3 New Filers

Jun 10, 2023, 5:30 AM EDT - 2 years ago

U.S. IPO Weekly Recap: No IPOs, But The Pipeline Gets A Pickup With 3 New Filers

BOF CAVA PXDT SRFM

dln101
dln101 Aug. 7 at 3:21 PM
$AZTR this penny looks done dumping, bounce from here with other pennies $KAVL $BTOG 🤔💪📈
1 · Reply
Sky360
Sky360 Aug. 5 at 6:51 PM
$AZTR Key Factors Influencing Azitra’s Next Financial Report Historical Financial Performance1 Q1 2025 Results: EPS: Improved year-over-year (YoY) to -$0.23, up 94.68% from prior periods, but still deeply negative. Cash Burn: Operating cash flow was -$3.07M, while financing activities provided $1.75M via capital raises. Revenue: Minimal at $7.5K in Q2 2024 (latest reported revenue), highlighting reliance on funding over commercial traction. Upcoming Estimates 626 Consensus EPS for Q2 2025: Expected to narrow slightly to -$0.21, reflecting ongoing losses typical of clinical-stage biopharma firms. EBIT Forecast: Projected to worsen to -$3.4M (vs. -$3.07M in Q1 2025), likely due to increased R&D spending for clinical trials. Revenue Expectations: Analysts anticipate $0.000 for Q2 2025, consistent with the company’s pre-revenue status.
1 · Reply
triclkbao1
triclkbao1 Aug. 5 at 1:28 PM
$AZTR Er on 8/12.
0 · Reply
pbacher
pbacher Aug. 4 at 5:00 PM
$AZTR ...
0 · Reply
pbacher
pbacher Aug. 1 at 2:54 PM
$AZTR is this manipulation or just bullshit? didn´t get it...
0 · Reply
Stmkr
Stmkr Aug. 1 at 2:43 PM
$AZTR Wow. Not good...
2 · Reply
EdgeLeak
EdgeLeak Jul. 31 at 7:37 PM
$AZTR For accountability I have sold aLL - 38k loss - was a hero or zero type of setup - GLTA
0 · Reply
pbacher
pbacher Jul. 31 at 7:33 PM
$AZTR unbelievable...
0 · Reply
pbacher
pbacher Jul. 31 at 3:47 PM
$AZTR what a shit show. Dont know why I'm atill here =D maybe for the sentiment
0 · Reply
pbacher
pbacher Jul. 31 at 3:16 PM
$AZTR great work so far =D which bottom do you mean?
0 · Reply
EdgeLeak
EdgeLeak Jul. 30 at 7:58 PM
$AZTR bottom signal post
1 · Reply
RipVanWinkleman
RipVanWinkleman Jul. 30 at 3:36 PM
$AZTR One year has passed since pos was above 1.00, but noq .18. When suddenly down to OTC?
1 · Reply
pbacher
pbacher Jul. 30 at 3:14 PM
$AZTR bullshit....
0 · Reply
dln101
dln101 Jul. 30 at 1:56 PM
$OP $VYNT bio pennies rallies coming to these beaten down stocks soon 👉 $AZTR $VTAK 🤔📈
0 · Reply
pbacher
pbacher Jul. 29 at 2:08 PM
$AZTR wow... this position
1 · Reply
pbacher
pbacher Jul. 29 at 8:24 AM
$AZTR look at this shit. every pharma stock going up. Come on. give us at least a simpathy play...
0 · Reply
bradtopshotcaller
bradtopshotcaller Jul. 29 at 3:52 AM
$AZTR cmon let’s get this rocket going already 🤑
1 · Reply
EdgeLeak
EdgeLeak Jul. 28 at 11:34 PM
$AZTR
1 · Reply
davooo
davooo Jul. 28 at 3:36 PM
$AZTR 🙄
1 · Reply
pbacher
pbacher Jul. 28 at 2:00 PM
$AZTR haha, just laughing. what a shit show from this stock. so frustrating. Again new ATL
0 · Reply
Affen
Affen Jul. 27 at 9:46 PM
$AZTR can anyone tell me what I'm not seeing? Looks like more dilution is possible very soon here
0 · Reply
MGeronimo
MGeronimo Jul. 27 at 2:05 AM
$AZTR IN HEAVY AT .22 10x normal buy in …lottery ticket on a solid growth stock
2 · Reply